389 related articles for article (PubMed ID: 26945421)
41. Breast MRI phenotype and background parenchymal enhancement may predict tumor response to neoadjuvant endocrine therapy.
Hilal T; Covington M; Kosiorek HE; Zwart C; Ocal IT; Pockaj BA; Northfelt DW; Patel BK
Breast J; 2018 Nov; 24(6):1010-1014. PubMed ID: 30066421
[TBL] [Abstract][Full Text] [Related]
42. Local radiotherapy alone following neoadjuvant chemotherapy and surgery in combined clinical stage II and III breast cancer.
White R; Dinneen T; Makris A
Radiat Oncol; 2016 Jul; 11():93. PubMed ID: 27457764
[TBL] [Abstract][Full Text] [Related]
43. Magnetic resonance imaging enhancement features before and after neoadjuvant chemotherapy in patients with breast cancer: a predictive value for responders.
Kang DK; Kim TH; Han TS; Kim KS; Yim H
J Comput Assist Tomogr; 2013; 37(3):432-9. PubMed ID: 23674017
[TBL] [Abstract][Full Text] [Related]
44. Association of breast cancer with MRI background parenchymal enhancement: the IMAGINE case-control study.
Watt GP; Sung J; Morris EA; Buys SS; Bradbury AR; Brooks JD; Conant EF; Weinstein SP; Kontos D; Woods M; Colonna SV; Liang X; Stein MA; Pike MC; Bernstein JL
Breast Cancer Res; 2020 Dec; 22(1):138. PubMed ID: 33287857
[TBL] [Abstract][Full Text] [Related]
45. Effect of Imaging Parameter Thresholds on MRI Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes.
Lo WC; Li W; Jones EF; Newitt DC; Kornak J; Wilmes LJ; Esserman LJ; Hylton NM
PLoS One; 2016; 11(2):e0142047. PubMed ID: 26886725
[TBL] [Abstract][Full Text] [Related]
46. Impact of Time from Completion of Neoadjuvant Chemotherapy to Surgery on Survival Outcomes in Breast Cancer Patients.
Sanford RA; Lei X; Barcenas CH; Mittendorf EA; Caudle AS; Valero V; Tripathy D; Giordano SH; Chavez-MacGregor M
Ann Surg Oncol; 2016 May; 23(5):1515-21. PubMed ID: 26678405
[TBL] [Abstract][Full Text] [Related]
47. Analysis of background parenchymal echogenicity on breast ultrasound: Correlation with mammographic breast density and background parenchymal enhancement on magnetic resonance imaging.
Ko KH; Jung HK; Kim I
Medicine (Baltimore); 2017 Aug; 96(33):e7850. PubMed ID: 28816987
[TBL] [Abstract][Full Text] [Related]
48. Prognostic Value of 68Ga-NOTA-RGD PET/CT for Predicting Disease-Free Survival for Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy and Surgery: A Comparison Study With Dynamic Contrast Enhanced MRI.
Kim YI; Yoon HJ; Paeng JC; Cheon GJ; Lee DS; Chung JK; Kim EE; Moon WK; Kang KW
Clin Nucl Med; 2016 Aug; 41(8):614-20. PubMed ID: 27276207
[TBL] [Abstract][Full Text] [Related]
49. Predicting local recurrence following breast-conserving treatment: parenchymal signal enhancement ratio (SER) around the tumor on preoperative MRI.
Kim MY; Cho N; Koo HR; Yun BL; Bae MS; Chie EK; Moon WK
Acta Radiol; 2013 Sep; 54(7):731-8. PubMed ID: 23550189
[TBL] [Abstract][Full Text] [Related]
50. Cavity margin status is an independent risk factor for local-regional recurrence in breast cancer patients treated with neoadjuvant chemotherapy before breast-conserving surgery.
Chen K; Jia W; Li S; He J; Zeng Y; Yang H; Jin L; Wu X; Su F
Am Surg; 2011 Dec; 77(12):1700-6. PubMed ID: 22273234
[TBL] [Abstract][Full Text] [Related]
51. Contralateral parenchymal enhancement on dynamic contrast-enhanced MRI reproduces as a biomarker of survival in ER-positive/HER2-negative breast cancer patients.
van der Velden BHM; Sutton EJ; Carbonaro LA; Pijnappel RM; Morris EA; Gilhuijs KGA
Eur Radiol; 2018 Nov; 28(11):4705-4716. PubMed ID: 29736850
[TBL] [Abstract][Full Text] [Related]
52. Evaluation with 3.0-T MR imaging: predicting the pathological response of triple-negative breast cancer treated with anthracycline and taxane neoadjuvant chemotherapy.
Kim MJ; Kim EK; Park S; Moon HJ; Kim SI; Park BW
Acta Radiol; 2015 Sep; 56(9):1069-77. PubMed ID: 25228161
[TBL] [Abstract][Full Text] [Related]
53. Clinical and pathological predictors of recurrence in breast cancer patients achieving pathological complete response to neoadjuvant chemotherapy.
Asaoka M; Narui K; Suganuma N; Chishima T; Yamada A; Sugae S; Kawai S; Uenaka N; Teraoka S; Miyahara K; Kawate T; Sato E; Nagao T; Matsubara Y; Gandhi S; Takabe K; Ishikawa T
Eur J Surg Oncol; 2019 Dec; 45(12):2289-2294. PubMed ID: 31787153
[TBL] [Abstract][Full Text] [Related]
54. Association Between Background Parenchymal Enhancement and Pathologic Complete Remission Throughout the Neoadjuvant Chemotherapy in Breast Cancer Patients.
You C; Peng W; Zhi W; He M; Liu G; Xie L; Jiang L; Hu X; Shen X; Gu Y
Transl Oncol; 2017 Oct; 10(5):786-792. PubMed ID: 28806712
[TBL] [Abstract][Full Text] [Related]
55. Do Calcifications Seen on Mammography After Neoadjuvant Chemotherapy for Breast Cancer Always Need to Be Excised?
Feliciano Y; Mamtani A; Morrow M; Stempel MM; Patil S; Jochelson MS
Ann Surg Oncol; 2017 Jun; 24(6):1492-1498. PubMed ID: 28058550
[TBL] [Abstract][Full Text] [Related]
56. Long-term Survival in Breast Cancer Patients Is Associated with Contralateral Parenchymal Enhancement at MRI: Outcomes of the SELECT Study.
Ragusi MAA; van der Velden BHM; Meeuwis C; Tetteroo E; Coerkamp EG; van Nijnatten TJA; Jansen FH; Wolters-van der Ben EJM; Jongen L; van Raamt F; Dorrius MD; Verloop J; Viergever MA; Pijnappel RM; Elias SG; Gilhuijs KGA
Radiology; 2023 May; 307(4):e221922. PubMed ID: 36975820
[TBL] [Abstract][Full Text] [Related]
57. Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL.
Hylton NM; Gatsonis CA; Rosen MA; Lehman CD; Newitt DC; Partridge SC; Bernreuter WK; Pisano ED; Morris EA; Weatherall PT; Polin SM; Newstead GM; Marques HS; Esserman LJ; Schnall MD;
Radiology; 2016 Apr; 279(1):44-55. PubMed ID: 26624971
[TBL] [Abstract][Full Text] [Related]
58. Assessment of Background Parenchymal Enhancement at Dynamic Contrast-enhanced MRI in Predicting Breast Cancer Recurrence Risk.
Arefan D; Zuley ML; Berg WA; Yang L; Sumkin JH; Wu S
Radiology; 2024 Jan; 310(1):e230269. PubMed ID: 38259203
[TBL] [Abstract][Full Text] [Related]
59. Population-Based Assessment of the Association Between Magnetic Resonance Imaging Background Parenchymal Enhancement and Future Primary Breast Cancer Risk.
Arasu VA; Miglioretti DL; Sprague BL; Alsheik NH; Buist DSM; Henderson LM; Herschorn SD; Lee JM; Onega T; Rauscher GH; Wernli KJ; Lehman CD; Kerlikowske K
J Clin Oncol; 2019 Apr; 37(12):954-963. PubMed ID: 30625040
[TBL] [Abstract][Full Text] [Related]
60. Contrast-enhanced MRI after neoadjuvant chemotherapy of breast cancer: lesion-to-background parenchymal signal enhancement ratio for discriminating pathological complete response from minimal residual tumour.
Kim SY; Cho N; Shin SU; Lee HB; Han W; Park IA; Kwon BR; Kim SY; Lee SH; Chang JM; Moon WK
Eur Radiol; 2018 Jul; 28(7):2986-2995. PubMed ID: 29380033
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
